{"schema_version":"secwatch.filing_event.v1","accession":"0001581280-26-000012","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.524890+00:00","generated_at":"2026-05-16T10:52:09.481585+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Twist Bioscience preliminary Q1 FY2026 revenue ~$103.7M, up 17% YoY, ahead of guidance","bullets":["Preliminary Q1 FY2026 revenue ~$103.7M (+/- $0.2M), 17% YoY growth, above guidance of $100-101M.","DNA Synthesis & Protein Solutions revenue $51.1M (+/- $0.1M), up 27% YoY.","NGS Applications revenue $52.6M (+/- $0.1M), ahead of guidance; excluding one customer transition, NGS grew 18% YoY.","Full Q1 financial results to be reported on Feb 2, 2026, before market open."],"urls":{"canonical":"https://secwatch.observer/filing/0001581280-26-000012","json":"https://secwatch.observer/filing/0001581280-26-000012.json","markdown":"https://secwatch.observer/filing/0001581280-26-000012.md","text":"https://secwatch.observer/filing/0001581280-26-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000158128026000012/0001581280-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000158128026000012/twist-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:52:09.481585+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}